|
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T-cell responses Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, in order to accelerate the development of the R&D pipeline |
|
oligoDOM® technology platform leverages:
Osivax lead program is a game-changing universal influenza vaccine
Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertises
Osivax remains open to collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens
(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.
- More than 10 years of R&D on a breakthrough approach to induce CD8 T-cell immunity
- A promising lead candidate of universal influenza vaccine
- Additional development opportunities, especially in cancer immunotherapies
Osivax lead program is a game-changing universal influenza vaccine
- Leveraging oligoDOM® technology, Osivax’s team is developing a standalone recombinant vaccine to prevent moderate to severe cases of seasonal and pandemic influenza
- This oligoDOM®-based universal influenza vaccine induces powerful CD8 T-cell immune responses against the highly conserved flu NucleoProtein (NP) and won’t require annual updates as NP is a highly conserved antigen
- The aim of this universal Influenza vaccine is to provide greater than 70% protection from morbidity and mortality caused by current and future A- and B-strain influenza viruses (1)
Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertises
Osivax remains open to collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens
(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.